These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

At week 52, results showed AChR+ patients treated with inebilizumab continued to improve based on the change from baseline in MG-ADL score vs placebo. Treatment with inebilizumab was associated ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 ...

At week 52, results showed AChR+ patients treated with inebilizumab continued to improve based on the change from baseline in MG-ADL score vs placebo. Treatment with inebilizumab was associated with ...

72.3% of AChR+ patients on Uplizna saw a ≥3-point MG-ADL score improvement vs. 45.2% on placebo. Uplizna is under FDA priority review for IgG4-related disease with a PDUFA date of April 3.

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with ...

The Phase 3 MINT trial, which was a randomized-control trial, evaluated Uplinza in muscle-specific kinase autoantibody-positive and AChR+ gMG patients, with the MuSK+ group followed for 26 weeks ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.